Is CG Oncology, Inc. (NASDAQ:CGON) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating CG Oncology, Inc. at current levels.
A single-asset bladder cancer bet where the Phase 3 readout already happened, and the commercial build is the real catalyst.
Where CGON is headed
By the back half of 2027, CG Oncology is no longer a clinical-stage story. Cretostimogene is FDA-approved, sitting in urology clinics as the preferred non-surgical option for high-risk BCG-unresponsive NMIBC, and it's competing directly with Merck's Keytruda and ImmunityBio's Anktiva in a market where urologists have been begging for something they can actually administer in-office without sending patients down the systemic immunotherapy path. The BOND-003 Cohort C data, with a complete response rate north of 75% and durability past 12 months, did something rare in oncology: it gave practicing urologists a drug that fits their existing workflow. Intravesical delivery, manageable safety, no cytokine release worries. That's a commercial profile, not just a clinical one.
Read the full Compass Direction on CGON
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $56.67).
See the full CGON analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is CG Oncology, Inc. (NASDAQ:CGON) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating CG Oncology, Inc. at current levels. A single-asset bladder cancer bet where the Phase 3 readout already happened, and the commercial build is the real catalyst.
What is CGON's Compass Score?
CG Oncology, Inc. scores 86/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for CGON?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CGON page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.